Free Trial
→ I was right about SpaceX (From Brownstone Research) (Ad)tc pixel Free BNTX Stock Alerts

BioNTech (BNTX) Financials

BioNTech logo
$92.50 -2.76 (-2.89%)
As of 01:43 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for BioNTech

Annual Income Statements for BioNTech

This table shows BioNTech's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -103 -55 -201 19 11,649 10,093 1,029 -689 -1,333
Consolidated Net Income / (Loss)		 -103 -55 -201 19 11,649 10,093 1,029 -689 -1,333
Net Income / (Loss) Continuing Operations		 -103 -55 -201 19 11,649 10,093 1,029 -689 -1,333
Total Pre-Tax Income 		-103 -55 -201 -178 17,030 13,858 1,312 -701 -1,233
Total Operating Income		 -74 -62 -204 -101 17,298 13,525 764 -1,360 -1,649
Total Gross Profit		 63 130 102 517 18,183 15,315 3,561 2,287 2,615
Total Revenue		 74 146 122 589 21,478 18,519 4,225 2,848 3,368
Operating Revenue		 74 146 122 589 21,478 18,519 4,225 2,848 3,368
Total Cost of Revenue		 11 16 20 72 3,295 3,204 663 560 753
Operating Cost of Revenue		 11 16 20 72 3,295 3,204 663 560 753
Total Operating Expenses		 136 192 305 617 884 1,790 2,797 3,648 4,264
Selling, General & Admin Expense		 28 30 51 115 313 515 548 550 604
Marketing Expense		 7.93 3.48 3.03 18 57 64 69 70 129
Research & Development Expense		 103 164 254 788 1,074 1,644 1,972 2,333 2,470
Other Operating Expenses / (Income)		 -2.48 -5.35 -2.24 -303 -560 -434 208 694 1,061
Total Other Income / (Expense), net		 -30 7.09 2.36 -77 -269 333 548 659 416
Interest Expense		 32 2.02 2.24 79 345 20 26 28 82
Interest & Investment Income		 2.56 9.21 4.60 1.95 77 353 575 687 497
Income Tax Expense		 0.05 0.69 -0.22 -197 5,380 3,765 283 -13 100
Basic Earnings per Share		 ($0.61) ($0.25) ($0.85) $0.06 $42.18 $41.49 $4.28 ($2.87) ($5.52)
Weighted Average Basic Shares Outstanding		 - - - 241.52B 246.81M 240.99M 237.73M 239.97M 239.97M
Diluted Earnings per Share		 ($0.61) ($0.25) ($0.85) $0.06 $39.63 $40.41 $4.24 ($2.87) ($5.52)
Weighted Average Diluted Shares Outstanding		 - - - 241.52B 246.81M 240.99M 237.73M 239.97M 239.97M
Weighted Average Basic & Diluted Shares Outstanding		 - - - 241.52B 246.81M 240.99M 237.73M 239.97M 239.97M

Quarterly Income Statements for BioNTech

No quarterly income statements for BioNTech are available.

Annual Cash Flow Statements for BioNTech

This table details how cash moves in and out of BioNTech's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -128 275 121 900 473 13,033 6,313 809 419
Net Cash From Operating Activities		 -63 -67 -223 -16 1,007 13,404 1,558 410 -1,059
Net Cash From Continuing Operating Activities		 -58 -67 -223 -16 1,022 13,404 1,558 410 -1,059
Net Income / (Loss) Continuing Operations		 -103 -55 -201 -178 17,030 10,093 1,029 -689 -1,333
Consolidated Net Income / (Loss)		 -103 -55 -201 -178 17,030 10,093 1,029 -689 -1,333
Depreciation Expense		 13 25 38 47 85 132 203 308 449
Non-Cash Adjustments To Reconcile Net Income		 35 9.09 35 230 -22 3,088 194 4.76 675
Changes in Operating Assets and Liabilities, net		 -2.44 -47 -94 -116 -16,071 91 132 785 -849
Net Cash From Investing Activities		 -63 -76 -87 -177 -641 50 5,572 401 1,490
Net Cash From Continuing Investing Activities		 -23 -76 -87 -177 -622 50 5,572 401 1,490
Acquisitions		 0.00 0.00 -6.85 -74 -24 0.00 -373 0.00 219
Sale of Property, Plant & Equipment		 6.24 0.81 0.00 1.47 - 0.64 5,945 401 1,272
Net Cash From Financing Activities		 -1.97 418 430 1,093 107 99 -817 -2.38 -13
Net Cash From Continuing Financing Activities		 -1.97 418 430 1,093 107 99 -817 -2.38 -13
Repayment of Debt		 -1.97 -2.46 -3.48 -17 -75 -20 -0.11 -2.38 -21
Repurchase of Preferred Equity		 - - - - 0.00 - -817 0.00 0.00
Issuance of Debt		 0.00 6.41 12 191 0.00 0.86 0.33 0.00 7.86

Quarterly Cash Flow Statements for BioNTech

No quarterly cash flow statements for BioNTech are available.

Annual Balance Sheets for BioNTech

This table presents BioNTech's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 747 895 2,832 17,917 24,904 25,450 23,320 25,806
Total Current Assets		 514 629 2,036 17,059 23,452 21,601 19,464 18,950
Cash & Equivalents		 471 583 1,478 1,916 14,844 12,902 10,105 9,008
Accounts Receivable		 22 13 202 14,014 7,644 2,385 1,515 1,085
Inventories, net		 6.63 13 78 569 470 396 293 130
Current Deferred & Refundable Income Taxes		 1.02 0.85 1.10 0.45 0.43 198 52 62
Other Current Assets		 13 17 276 128 291 316 231 213
Other Current Nonoperating Assets		 0.38 1.89 - 432 203 5,404 7,268 8,452
Plant, Property, & Equipment, net		 76 104 277 365 652 838 968 1,269
Plant, Property & Equipment, gross		 76 104 277 365 652 838 968 1,269
Total Noncurrent Assets		 158 162 519 493 800 3,011 2,889 5,588
Goodwill		 - - - - 65 401 394 432
Intangible Assets		 101 100 200 229 170 889 818 1,885
Noncurrent Deferred & Refundable Income Taxes		 - 0.00 197 0.00 246 90 85 16
Other Noncurrent Operating Assets		 57 62 122 264 319 1,630 1,592 3,255
Total Liabilities & Shareholders' Equity		 747 895 2,832 17,917 24,904 25,450 23,320 25,806
Total Liabilities		 442 341 1,157 4,456 3,449 3,054 3,228 3,244
Total Current Liabilities		 144 155 740 3,940 3,157 2,290 2,612 2,514
Short-Term Debt		 9.46 5.96 11 - 840 459 1,494 413
Accounts Payable		 48 23 125 181 218 392 442 628
Current Deferred & Payable Income Tax Liabilities		 0.34 0.17 0.00 1,776 637 581 4.66 77
Other Current Liabilities		 87 126 604 1,984 1,461 858 671 1,397
Total Noncurrent Liabilities		 297 186 416 516 292 763 616 730
Long-Term Debt		 - 77 282 - 6.53 43 49 111
Capital Lease Obligations		 - - - 194 188 211 222 253
Noncurrent Deferred & Payable Income Tax Liabilities		 - 0.00 0.24 80 18 44 44 99
Other Noncurrent Operating Liabilities		 297 109 134 241 79 465 302 267
Total Equity & Noncontrolling Interests		 306 554 1,676 13,461 21,455 22,396 20,092 22,562
Total Preferred & Common Equity		 305 554 1,676 13,461 21,455 22,396 20,092 22,562
Total Common Equity		 305 554 1,676 13,461 21,455 22,396 20,092 22,562
Common Stock		 221 261 301 279 266 275 257 304
Retained Earnings		 - - -500 11,185 20,148 21,862 19,768 21,080
Treasury Stock		 0.00 -6.20 -5.86 -4.30 -5.67 -12 -8.90 -9.04
Other Equity Adjustments		 365 776 1,881 2,001 1,048 271 76 1,187

Quarterly Balance Sheets for BioNTech

No quarterly balance sheets for BioNTech are available.

Annual Metrics And Ratios for BioNTech

This table displays calculated financial ratios and metrics derived from BioNTech's official financial filings.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - - - - - - 479,941,608.00
DEI Adjusted Shares Outstanding		 - - - - - - - - 479,941,608.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - -2.78
Growth Metrics		 - - - - - - - - -
Profitability Metrics		 - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -52 -43 -143 -70 11,833 9,850 599 -952 -1,154
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - 43.80% 2.59% -4.36% -4.95%
Earnings before Interest and Taxes (EBIT)		 -74 -62 -204 -101 17,298 13,525 764 -1,360 -1,649
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -61 -37 -166 -53 17,383 13,657 967 -1,052 -1,200
Valuation Ratios		 - - - - - - - - -
Leverage & Solvency		 - - - - - - - - -
Liquidity Ratios		 - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 122 -361 -509 1,016 13,714 3,240 -634 -2,548
Efficiency Ratios		 - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - -
Invested Capital		 0.00 -165 53 491 11,308 7,444 4,803 4,485 5,878
Increase / (Decrease) in Invested Capital		 0.00 -165 218 438 10,817 -3,864 -2,641 -318 1,394
Book Value per Share		 $0.00 $30.46 $55.38 $0.01 $0.06 $86.93 $92.93 $84.52 $94.02
Tangible Book Value per Share		 $0.00 $20.39 $45.35 $0.01 $0.05 $85.98 $87.58 $79.42 $84.36
Total Capital		 0.00 307 637 1,969 13,656 22,490 23,110 21,857 23,338
Total Debt		 0.00 0.00 83 293 194 1,035 713 1,765 777
Total Long-Term Debt		 0.00 0.00 77 282 194 195 254 271 364
Net Debt		 0.00 -471 -499 -1,185 -1,722 -13,809 -12,189 -8,340 -8,231
Capital Expenditures (CapEx)		 23 33 80 103 174 352 -5,945 -401 -1,272
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -101 -103 -171 11,203 6,292 6,868 8,241 7,840
Debt-free Net Working Capital (DFNWC)		 0.00 369 480 1,307 13,118 21,136 19,770 18,346 16,848
Net Working Capital (NWC)		 0.00 369 474 1,296 13,118 20,296 19,311 16,852 16,435
Net Nonoperating Expense (NNE)		 52 12 59 -89 184 -243 -430 -264 179
Net Nonoperating Obligations (NNO)		 0.00 -472 -501 -1,185 -2,153 -14,011 -17,593 -15,608 -16,683
Total Depreciation and Amortization (D&A)		 13 25 38 47 85 132 203 308 449
Earnings Adjustments		 - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($0.85) $0.06 $0.00 $38.78 $3.87 ($2.87) ($5.52)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 241.52B 0.00 240.99M 237.73M 239.97M 239.97M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($0.85) $0.06 $0.00 $37.77 $3.83 ($2.87) ($5.52)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 241.52B 0.00 240.99M 237.73M 239.97M 239.97M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($0.85) $0.06 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 241.52B 0.00 240.99M 237.73M 239.97M 239.97M
Normalized Net Operating Profit after Tax (NOPAT)		 -52 -43 -143 -70 11,833 9,850 599 -952 -1,154
Debt Service Ratios		 - - - - - - - - -
Payout Ratios		 - - - - - - - - -

Quarterly Metrics And Ratios for BioNTech

No quarterly metrics and ratios for BioNTech are available.


Financials Breakdown Chart

Frequently Asked Questions About BioNTech's Financials

When does BioNTech's fiscal year end?

According to the most recent income statement we have on file, BioNTech's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

How has BioNTech's net income changed over the last 8 years?

BioNTech's net income appears to be on an upward trend, with a most recent value of -$1.33 billion in 2025, rising from -$103.25 million in 2017. The previous period was -$688.65 million in 2024. See BioNTech's forecast for analyst expectations on what’s next for the company.

What is BioNTech's operating income?
BioNTech's total operating income in 2025 was -$1.65 billion, based on the following breakdown:
  • Total Gross Profit: $2.61 billion
  • Total Operating Expenses: $4.26 billion
How has BioNTech's revenue changed over the last 8 years?

Over the last 8 years, BioNTech's total revenue changed from $73.99 million in 2017 to $3.37 billion in 2025, a change of 4,451.9%.

How much debt does BioNTech have?

BioNTech's total liabilities were at $3.24 billion at the end of 2025, a 0.5% increase from 2024, and a 634.4% increase since 2018.

How much cash does BioNTech have?

In the past 7 years, BioNTech's cash and equivalents has ranged from $470.96 million in 2018 to $14.84 billion in 2022, and is currently $9.01 billion as of their latest financial filing in 2025.

How has BioNTech's book value per share changed over the last 8 years?

Over the last 8 years, BioNTech's book value per share changed from 0.00 in 2017 to 94.02 in 2025, a change of 9,401.8%.


Related Companies

Financial statements for NASDAQ:BNTX last updated on 3/19/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel